Agent for reversing resistance to anticancer drugs
AssigneesY's AC Co., Ltd., Juntendo Educational Foundation
InventorsChikao Morimoto, Kei Ohnuma, Ryo Hatano, Takumi Itoh, Yutaro Kaneko
Life of this patent
Estimating the term…
Loading patent…
AssigneesY's AC Co., Ltd., Juntendo Educational Foundation
InventorsChikao Morimoto, Kei Ohnuma, Ryo Hatano, Takumi Itoh, Yutaro Kaneko
Estimating the term…
Provided is the present invention focusing on roles of IL-26 present in humans but not in mice by characterizing molecular mechanisms involved in interspecies differences in terms of efficacy of EGFR-TKI. The present inventors found that human cancers are exposed to IL-26 in a tumor microenvironment (TME), activating the EGFR-TKI bypass pathway, while suppression of IL-26 overcomes EGFR-TKI resistance in cancers. Furthermore, the present inventors identified EphA3 as a new functional receptor for IL-26 of TNBC. Therefore, the present invention provides a pharmaceutical composition for use in combination with an anticancer drug for treating cancer in a patient, the pharmaceutical composition containing a drug that reverses resistance to the anticancer drug by IL-26 as an active ingredient. Furthermore, the present invention provides a humanized anti-IL-26 antibody, and a therapeutic or preventive agent for refractory immune disorders or cancer using the antibody.
A pharmaceutical composition for use in combination with an anticancer drug, the pharmaceutical composition comprising, as an active ingredient, a drug that reverses resistance to the anticancer drug due to IL-26 in a cancer.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for improving responsiveness to an anticancer drug in cancer patients having a low sensitivity to the anticancer drug or exhibiting resistance to the anticancer drug, the method comprising inhibiting IL-26 in a cancer microenvironment of the cancer patients.
A method for treating cancer in cancer patients having a low sensitivity to an anticancer drug or exhibiting resistance to an anticancer drug, the method comprising inhibiting IL-26 of the cancer patients and administering an anticancer drug to the cancer patients.
-43. (canceled)
Dependencies are inferred from the claim text.